SBStephanie D. Burr

Stephanie D. Burr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephanie D. Burr has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Anderson

    Carle Illinois College of Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA

    1 shared publication
  • Cailin E. McMahon

    Molecular Biology and Genetics Department; Cornell College of Agriculture and Life Sciences, Ithaca, USA

    1 shared publication
  • Daniel Lindén

    Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    1 shared publication
  • Hanmei Bao

    Barshop Institute for Longevity and Aging Studies and Department of Medicine, Division of Diabetes; University of Texas Health San Antonio, San Antonio, USA

    1 shared publication
  • Jun Liu

    Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA

    1 shared publication
  • Katja Madeyski-Bengtson

    Translational Genomics, Discovery Sciences; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

    1 shared publication

Latest Publications

  • Top Cited Papers
    Open Access

    PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein

    by Scott M. Johnson, Hanmei Bao, Cailin E. McMahon, Yongbin Chen, Stephanie D. Burr, Aaron M. Anderson, Katja Madeyski-Bengtson, Daniel Lindén, Xianlin Han, Jun Liu

    The I148M variant of PNPLA3 is closely associated with hepatic steatosis. Recent evidence indicates that the I148M mutant functions as an inhibitor of PNPLA2/ATGL-mediated lipolysis, leaving the role of wild-type PNPLA3 undefined. Despite showing a triglyceride hydrolase activity in vitro, PNPLA3 has yet to be established as a lipase in vivo. Here, we show that PNPLA3 preferentially hydrolyzes polyunsaturated triglycerides, mobilizing polyunsaturated fatty acids for phospholipid desaturation and enhancing hepatic secretion of triglyceride-rich lipoproteins. Under lipogenic conditions, mice with liver-specific knockout or acute knockdown of PNPLA3 exhibit aggravated liver steatosis and reduced plasma VLDL-triglyceride levels. Similarly, I148M-knockin mice show decreased hepatic triglyceride secretion during lipogenic stimulation. Our results highlight a specific context whereby the wild-type PNPLA3 facilitates the balance between hepatic triglyceride storage and secretion, and suggest the potential contribution of a loss-of-function by the I148M variant to the development of fatty liver disease in humans.